Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,185 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: intravenous saline Clear all
Recruiting Phase 2 Interventional

Tocilizumab in Lung Transplantation

NCT06033196
View directory record Official record
Conditions
Lung Transplant
Interventions
Tocilizumab, Placebo for Tocilizumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 75 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
21
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 5, 2026, 5:54 AM EDT
Recruiting No phase listed Observational

Depression and Driving

NCT05446805
View directory record Official record
Conditions
Depression, Drive
Interventions
F 18 AV-1451 (Flortaucipir), [11C]-Pittsburgh Compound B ([11C]PiB)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
65 Years and older
Enrollment
150 participants
Timeline
2021 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Naloxone for Optimizing Hypoxemia Of Lung Donors

NCT02581111
View directory record Official record
Conditions
Brain Death, Organ Donors, Lung Transplantation
Interventions
Naloxone, Normal saline
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
13 Years to 70 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Denver, Colorado • Metairie, Louisiana • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Not applicable Interventional Results available

Zoledronic Acid for Osteoporosis in the Elderly

NCT00558012
View directory record Official record
Conditions
Osteoporosis, Bone Loss, Fragility Fractures
Interventions
Intravenous zoledronic acid, Vitamin D 800 IU/daily, Calcium 1200 mg/daily
Drug · Dietary Supplement
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years and older · Female only
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2015 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Phase 4 Interventional Results available

A Pilot Study to Determine the Efficacy of Intravenous Ibuprofen for Pain Control Following Arthroscopic Knee Surgery

NCT01650519
View directory record Official record
Conditions
Arthroscopic Knee Surgery
Interventions
IV ibuprofen, IV ketorolac
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Citalopram Effects on Craving and Dopamine Receptor Availability in Alcoholics

NCT01657760
View directory record Official record
Conditions
Alcohol Dependence
Interventions
citalopram
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 5, 2026, 5:54 AM EDT
Recruiting Phase 3 Interventional

Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient

NCT04268849
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferumoxytol, Saline, Ferrous sulfate tablets, Vitamin C
Drug
Lead sponsor
Auerbach Hematology Oncology Associates P C
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Phase 2 Interventional Results available

Rilonacept to Improve Artery Function in Patients With Atherosclerosis

NCT00417417
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis, Inflammation, Endothelial Dysfunction
Interventions
Rilonacept, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Phase 4 Interventional

Impact of Nesiritide Infusion for Decompensated Heart Failure in the Emergency Department

NCT00559338
View directory record Official record
Conditions
Heart Failure, Congestive, Cardiomyopathy
Interventions
recombinant B-type, natriuretic peptide, placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2007 · Synced Oct 5, 2026, 5:54 AM EDT
Terminated Phase 2 Interventional

Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts in Sepsis Patients

NCT03821038
View directory record Official record
Conditions
Sepsis, Severe
Interventions
CYT107, Placebos
Biological · Drug
Lead sponsor
Revimmune
Industry
Eligibility
18 Years to 85 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Gainesville, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Does Tranexamic Acid Decrease Blood Loss in Pediatric Idiopathic Scoliosis Surgery?

NCT01813058
View directory record Official record
Conditions
Adolescent Idiopathic Scoliosis
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
10 Years to 21 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

NCT03867084
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Pembrolizumab, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
959 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
24
States / cities
Gilbert, Arizona • Tucson, Arizona • Duarte, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 5, 2026, 5:54 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Intraoperative Methadone for Postoperative Pain Control After Thoracic Surgery

NCT04525898
View directory record Official record
Conditions
Postoperative Pain
Interventions
Methadone
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Nebivolol on Skeletal Muscle During Exercise in Hypertensive Patients

NCT01501929
View directory record Official record
Conditions
Hypertension
Interventions
Metoprolol succinate, Nebivolol, Non-invasive measurement of Cardiac Output (CO), Endothelial cell collection, Microvascular perfusion assessment using Definity
Drug · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping

NCT05670730
View directory record Official record
Conditions
Duchenne Muscular Dystrophy, Exon 44
Interventions
AOC 1044, Placebo
Drug
Lead sponsor
Avidity Biosciences, Inc.
Industry
Eligibility
7 Years to 55 Years · Male only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
10
States / cities
Little Rock, Arkansas • La Jolla, California • Palo Alto, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 5, 2026, 5:54 AM EDT
Recruiting Phase 3 Interventional

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

NCT06901531
View directory record Official record
Conditions
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions
zolbetuximab, Pembrolizumab, Capecitabine, Oxaliplatin, Folinic acid (leucovorin or local equivalent), 5-fluorouracil (5-FU), Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
37
States / cities
Birmingham, Alabama • Bakersfield, California • Cerritos, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Phase 1Phase 2 Interventional

Zofin (Organicell Flow) for Patients With COVID-19

NCT04384445
View directory record Official record
Conditions
Corona Virus Infection, COVID-19, SARS, Acute Respiratory Distress Syndrome
Interventions
Zofin, Placebo
Biological · Other
Lead sponsor
ZEO ScientifiX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of LY3041658 in Healthy Participants

NCT02148627
View directory record Official record
Conditions
Healthy
Interventions
LY3041658 (SC), LY3041658 (IV), Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety Study of Efprezimod Alfa (CD24Fc, MK-7110) When Administered Intravenously in Healthy Adult Subjects (MK-7110-001)

NCT02650895
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Efprezimod alfa, Saline
Biological · Drug
Lead sponsor
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 5, 2026, 5:54 AM EDT
Withdrawn Phase 2 Interventional

Effect of Perioperative Intravenous Lidocaine on Postoperative Quality of Recovery in Patients Undergoing Spine Surgery

NCT01930877
View directory record Official record
Conditions
Pain
Interventions
Lidocaine, Placebo (normal saline)
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Not applicable Interventional

Fluid Resuscitation for Pediatric Diabetic Ketoacidosis

NCT01701557
View directory record Official record
Conditions
Diabetes
Interventions
slow fluid rate, fast fluid rate
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
1 Day to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Oct 5, 2026, 5:54 AM EDT
Terminated Phase 1 Interventional Results available

The Using Postoperative Ketamine and Exploring the Effect on Endometriosis Pain (UPKEEEP) Study

NCT05229653
View directory record Official record
Conditions
Endometriosis, Post Operative Pain
Interventions
Ketamine, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 5, 2026, 5:54 AM EDT
Completed Phase 3 Interventional Results available

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

NCT03515837
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
pembrolizumab, pemetrexed, carboplatin, cisplatin, saline solution
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
492 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
19
States / cities
Los Angeles, California • Monterey, California • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 5, 2026, 5:54 AM EDT
Completed No phase listed Observational

Cystic Breast Masses by Contrast Enhanced Ultrasound (CEUS)

NCT02887937
View directory record Official record
Conditions
Breast Cancer
Interventions
Definity
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 5, 2026, 5:54 AM EDT